Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical Confirms Advances for Accelerated Approval of Diamyd®
Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Srage 3 Diabetes Mellitus, Type 1.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
January 10, 2025
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process
Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1 in 12-28 year old patients.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
December 13, 2024
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial
Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1 in 12-28 year old patients.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical Pursues Accelerated Approval for Type 1 Diabetes Precision Medicine
Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
September 09, 2024
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical Receives Second FDA Fast Track Designation for Diamyd® in Type 1 Diabetes
Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
July 18, 2024
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Recruitment Milestone Reached in Diamyd® Phase 3 Trial
Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
April 12, 2024
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®
Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : GAD-alum,Vitamin D3
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin D3
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Vitamin D3
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin D3
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Dalim BioTech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cholecalciferol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypocalcemia.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 31, 2022
Lead Product(s) : Vitamin D3
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Dalim BioTech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin D3
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics Evaluation of Vitamin D Formulations
Details : Vitamin D3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Vitamin D.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 26, 2022
Lead Product(s) : Vitamin D3
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable